Christopher Lines

8.0k total citations · 1 hit paper
77 papers, 5.8k citations indexed

About

Christopher Lines is a scholar working on Cognitive Neuroscience, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Christopher Lines has authored 77 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Cognitive Neuroscience, 27 papers in Experimental and Cognitive Psychology and 26 papers in Psychiatry and Mental health. Recurrent topics in Christopher Lines's work include Sleep and Wakefulness Research (28 papers), Sleep and related disorders (27 papers) and Migraine and Headache Studies (18 papers). Christopher Lines is often cited by papers focused on Sleep and Wakefulness Research (28 papers), Sleep and related disorders (27 papers) and Migraine and Headache Studies (18 papers). Christopher Lines collaborates with scholars based in United States, United Kingdom and France. Christopher Lines's co-authors include David Michelson, Marvin A. Konstam, John A. Baron, Robert S. Sandler, Robert H. Riddell, James A. Bolognese, Dion Morton, Bettina Oxenius, Robert S. Bresalier and Kevin Horgan and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher Lines

75 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial

2005 1.9k citations Robert S. Bresalier, Robert S. Sandler et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Lines United States	33	1.8k	1.5k	1.5k	1.3k	1.1k	77	5.8k
Smriti Iyengar United States	30	1.6k 0.9×	1.8k 1.2×	954 0.7×	187 0.1×	195 0.2×	61	5.0k
Régis Bordet France	50	1.0k 0.6×	552 0.4×	881 0.6×	188 0.1×	288 0.3×	313	9.1k
Alessandro Martorana Italy	40	712 0.4×	538 0.4×	1.5k 1.0×	300 0.2×	252 0.2×	125	5.1k
Agostino Baruzzi Italy	47	2.1k 1.2×	334 0.2×	735 0.5×	239 0.2×	355 0.3×	200	7.2k
Zoe Arvanitakis United States	44	4.9k 2.8×	739 0.5×	991 0.7×	180 0.1×	496 0.5×	125	13.4k
Bruce J. Kinon United States	47	5.0k 2.9×	845 0.6×	882 0.6×	451 0.4×	200 0.2×	153	7.4k
Jun Horiguchi Japan	42	719 0.4×	226 0.1×	614 0.4×	358 0.3×	150 0.1×	383	7.2k
Seol‐Heui Han South Korea	38	1.3k 0.8×	395 0.3×	942 0.6×	123 0.1×	187 0.2×	185	5.5k
Lucette Lacomblez France	47	1.1k 0.6×	1.0k 0.7×	712 0.5×	180 0.1×	79 0.1×	154	10.3k
Shobha Dhadda United States	25	1.6k 0.9×	1.1k 0.7×	545 0.4×	295 0.2×	188 0.2×	70	5.4k

Countries citing papers authored by Christopher Lines

Since Specialization

Citations

This map shows the geographic impact of Christopher Lines's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Lines with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Lines more than expected).

Fields of papers citing papers by Christopher Lines

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Lines. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Lines. The network helps show where Christopher Lines may publish in the future.

Co-authorship network of co-authors of Christopher Lines

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Lines. A scholar is included among the top collaborators of Christopher Lines based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Lines. Christopher Lines is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Svetnik, Vladimir, Ting‐Chuan Wang, Paulette Ceesay, et al.. (2021). Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's disease. Journal of Sleep Research. 30(6). e13328–e13328. 14 indexed citations

Snyder, Ellen, Peining Tao, Vladimir Svetnik, Christopher Lines, & W. Joseph Herring. (2020). Use of the single‐item Patient Global Impression‐Severity scale as a self‐reported assessment of insomnia severity. Journal of Sleep Research. 30(1). 7 indexed citations

Svetnik, Vladimir, Ellen Snyder, Peining Tao, et al.. (2019). How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients?. Sleep Medicine. 67. 137–146. 11 indexed citations

Egan, Michael, Yuki Mukai, Tiffini Voss, et al.. (2019). Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease. Alzheimer s Research & Therapy. 11(1). 68–68. 63 indexed citations

Herring, W. Joseph, Kathryn M. Connor, Ellen Snyder, et al.. (2017). Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. Psychopharmacology. 234(11). 1703–1711. 16 indexed citations

Sun, Hong, John Palcza, Russell Rosenberg, et al.. (2015). Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 109(3). 416–426. 37 indexed citations

Uemura, Naoto, Jacqueline B. McCrea, Hong Sun, et al.. (2015). Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. The Journal of Clinical Pharmacology. 55(10). 1093–1100. 26 indexed citations

Stocchi, Fabrizio, Olivier Rascol, Robert A. Hauser, et al.. (2014). Phase-3 Clinical Trial of the Adenosine 2a Antagonist Preladenant, Given as Monotherapy, in Patients with Parkinson’s Disease (S7.004). Neurology. 82(10_supplement). 4 indexed citations

Egan, Michael, Xin Zhao, Ying Zhang, et al.. (2013). Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophrenia Research. 146(1-3). 224–230. 42 indexed citations

10.

Herring, W. Joseph, Ellen Snyder, Kerry Budd, et al.. (2012). Orexin receptor antagonism for treatment of insomnia. Neurology. 79(23). 2265–2274. 245 indexed citations

11.

Ho, Tony W., Eric Pearlman, Donald W. Lewis, et al.. (2012). Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. Cephalalgia. 32(10). 750–765. 54 indexed citations

12.

Ho, Tony W., Andrew P. Ho, Bernard Chaitman, et al.. (2012). Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease. Headache The Journal of Head and Face Pain. 52(2). 224–235. 52 indexed citations

13.

Cho, Yong‐Yeon, Paul Maruff, John T. Connell, et al.. (2011). Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology. 218(3). 513–524. 31 indexed citations

14.

Han, Tae Hyung, Rebecca Blanchard, John Palcza, et al.. (2010). The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects. PubMed. 3(4). 55–62. 9 indexed citations

15.

Boyle, Julia, et al.. (2008). Next‐day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double‐blind study in healthy elderly subjects. Human Psychopharmacology Clinical and Experimental. 24(1). 61–71. 13 indexed citations

16.

Thal, Leon J., Steven H. Ferris, Christopher Assaid, et al.. (2008). Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial. Current Alzheimer Research. 5(1). 73–82. 25 indexed citations

17.

Ho, Tony W., Michel D. Ferrari, David W. Dodick, et al.. (2008). Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. The Lancet. 372(9656). 2115–2123. 429 indexed citations

18.

Keller, Martin B., Stuart Montgomery, William A. Ball, et al.. (2005). Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder. Biological Psychiatry. 59(3). 216–223. 223 indexed citations

19.

Bresalier, Robert S., Robert S. Sandler, Hui Quan, et al.. (2005). Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. New England Journal of Medicine. 352(11). 1092–1102. 1855 indexed citations breakdown →

20.

Goldstein, Jerome, Robert Ryan, Kaihong Jiang, et al.. (1998). Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in Migraine. Headache The Journal of Head and Face Pain. 38(10). 737–747. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact